Skip to main content
https://pbs.twimg.com/media/Fkm302AXgAAjk4N.jpg
anti-IL-23 therapy is not effective in Axial Spondyloarthritis. While ustekinumab, guselkumab and risankizumab are approved in psoriasis (& PsA for GUS, RIZ), studies of Ustekinumab and risankizumab failed to show efficacy in axSpA https://t.co/hjXEopji6r https://t.co/FwzBa2YNzb
Dr. John Cush
22-12-2022
×